WO1996012010A1 - Preparation de mutants d'aav rep-negatifs et cellules pouvant etre utilisees a cet effet - Google Patents

Preparation de mutants d'aav rep-negatifs et cellules pouvant etre utilisees a cet effet Download PDF

Info

Publication number
WO1996012010A1
WO1996012010A1 PCT/DE1995/001429 DE9501429W WO9612010A1 WO 1996012010 A1 WO1996012010 A1 WO 1996012010A1 DE 9501429 W DE9501429 W DE 9501429W WO 9612010 A1 WO9612010 A1 WO 9612010A1
Authority
WO
WIPO (PCT)
Prior art keywords
rep
aav
negative
cells
dna
Prior art date
Application number
PCT/DE1995/001429
Other languages
German (de)
English (en)
Inventor
Christina HÖLSCHER
Alexander BÜRKLE
Jürgen KLEINSCHMIDT
Markus HÖRER
Harald Zur Hausen
Pierre Chambon
Regine Heilbronn
Original Assignee
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19944436664 external-priority patent/DE4436664A1/de
Priority claimed from DE19944436665 external-priority patent/DE4436665C2/de
Application filed by Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. filed Critical Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
Priority to EP95934604A priority Critical patent/EP0785991A1/fr
Priority to JP8512845A priority patent/JPH10507352A/ja
Publication of WO1996012010A1 publication Critical patent/WO1996012010A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the invention relates to the provision of rep-negative AAV mutants and cells which can be used therefor.
  • the invention further relates to an expression plasmid which can be used to produce the cells.
  • Adeno-associated viruses are single-stranded DNA viruses belonging to the parvovirus family. For their replication, AAVs need helper viruses, in particular adenoviruses or herpes viruses. In the absence of helper viruses, AAVs integrate into the host cell genome, particularly at a specific location on chromosome 19 or 17.
  • the 145 bp "inverted repeats" serve as the origin of replication and as ice signals for integration and packaging.
  • the cap gene codes for three structural proteins and the rep gene for a family of multifunctional regulator proteins.
  • the mRNAs for Rep 78 and its C-terminal spliced version Rep 68 start at the p5 promoter.
  • Two N-terminally shortened versions of Rep 78 and Rep 68, namely Rep 52 and Rep 40, are expressed under the control of the p19 promoter.
  • Rep proteins are necessary for AAV DNA replication. They are also required for AAV gene regulation.
  • AAVs suppress tumor development in animals. Furthermore, they suppress the cell transformation caused by oncogenes as well as the induced DNA amplification. Furthermore, AAVs have an antiproliferative activity. AAV Rep proteins are held responsible for the above activities. However, these activities are not assigned to the individual Rep proteins or domains thereof. This would be necessary in order to use AAVs therapeutically. One way to achieve this assignment is to examine AAVs that have mutations in the Rep proteins. Many attempts have been made in this regard. So far, however, it has not been possible to provide rep-negative AAV mutants which are free from wild-type AAV. However, such are indispensable for the above investigations.
  • the present invention is therefore based on the object of providing a means by which rep-negative AAV mutants can be obtained without the above disadvantages.
  • the invention thus relates to cells which stably express the AAV Rep proteins 78 and 52 and 40 and / or 68. Cells which express Rep proteins 78, 52 and 40 are preferred.
  • Cells according to the invention can be produced in the usual way.
  • Cells of the known HeM1 line are advantageously used as starting material (cf. "5th Parvovirus Workshop", Chrystal River, Florida, USA, Nov. 10-14, 1993). These cells express the AAV Rep proteins 78 and 52, the Rep 78 expression being under the control of dexamethasone-inducible MMTV-LTR.
  • HeM1 cells are transfected with an expression plasmid coding for Rep 40 and / or an expression plasmid coding for Rep 68 or an expression plasmid which codes for both Rep proteins.
  • An expression plasmid for Rep 40 is preferably used, the expression plasmid.
  • pCMRep 40 is very particularly preferred.
  • the cells obtained by transfection of pCMRep 40 stably express the AAV-Rep proteins Rep 78, Rep 52 and Rep 40. These cells were identified as cell line He 10-1, He 22-2 and He 5-5 in the DSM under DSM ACC2193 , DSM ACC2192 and DSM ACC2191 on September 28, 1994. Furthermore, the cells were deposited as cell line HeCMI g at DSM under DSM ACC2185 on August 30, 1994. The above cells are also an object of the invention.
  • Another object of the invention is a method for providing rep-negative AAV mutants.
  • Such a process comprises the following process steps:
  • process step (a) involves cotransfection with an expression plasmid coding for a glucocorticoid receptor.
  • an expression plasmid coding for a glucocorticoid receptor Such is known to the person skilled in the art. For example, he knows the expression plasmid HGO (cf. Kumar, V., et al., Cell 51 (1987), 941-951).
  • method step (a) implies the infection of cells according to the invention with a rep-negative AAV mutant.
  • the expression "DNA of a rep-negative AAV mutant” encompasses an AAV genome, optionally present in a vector, which has mutations in the rep gene. Such mutations can in particular be deletions, insertions and / or substitutions of one or more nucleotides.
  • the AAV DNA can also have a deletion of the entire region coding for Rep.
  • the DNA encoding Rep can be partially or completely replaced by a DNA encoding a foreign protein (peptide) or by a DNA encoding an "antisense” RNA.
  • the foreign protein (peptide) or the “antisense” RNA is preferably suitable for gene therapy measures.
  • the expression "rep-negative AAV mutant” therefore also implies the term "rep-negative AAV vector”.
  • DNA of a rep-negative AAV mutant also includes a DNA which, in addition to the mutations indicated above, has further mutations in other areas of AAV DNA.
  • This can e.g. Mutations in the cap gene.
  • an expressible AAV-cap gene is present in the cells according to the invention. This can be done by the means enabling AAV replication, e.g. the AAV helper virus. Methods are known to those skilled in the art, an AAV-cap gene, e.g. to insert into an AAV helper virus.
  • AAV helper virus includes viruses that allow AAVs to replicate. These are in particular adenoviruses, such as adenovirus-2, and herpes viruses.
  • Rep-negative AAV mutants are free from wild-type AAV, since recombination events, such as those that occur in cells with transient expression of Rep proteins, are avoided.
  • the present invention thus represents the basis for restricting the activities attributed to the Rep proteins to individual Rep proteins or domains thereof. This enables the mechanism of action of AAV as a tumor suppressive principle to be investigated in detail, which is essential for the use of AAV in tumor therapy.
  • the Framework of gene therapy can be used as viral vectors.
  • Rep-negative AAV mutants according to the invention can carry genes or gene segments that can be used for this purpose. These can lie in particular in the rep gene and / or cap gene. The present invention thus represents a breakthrough in the field of the production of vectors which can be used for gene therapies.
  • FIG. 1 shows a schematic representation of the Rep-coding DNA in the expression plasmid pCMRep40.
  • the start ATG triplet and the termination codon TGA are given, they correspond to those of the wild-type AAV genome.
  • the intron (position: 1907-2227) is removed by directed mutagenesis, so that Rep 40 can be expressed without splicing.
  • He 10-1 cells are transfected with the DNA of the known AAV Rep mutant pTAV 2-3.
  • pTAV2-3 has a "frame shift" mutation at position 1045, whereby all four Rep proteins are inactivated (cf. Heilbronn, R., et al., J. Virol. 64 (1990), 3012-3018).
  • the cells are harvested and the total cell DNA is isolated. This is cleaved with the restriction enzymes Xbal or Dpnl and analyzed in a Southern blot.
  • 32P P-labeled AAV-DNA is used as a hybridization sample.
  • the restriction enzyme Xbal does not cut AAV DNA, nor does the restriction enzyme Dpnl cleave any DNA replicated in eukaryotes. Replicated pTAV2-3 DNA is obtained.
  • the supernatant of the cells not harvested is alternately frozen and thawed and subjected to an ultrasound treatment. The supernatant is titrated on He10-1 cells.
  • the detection of infectious AAVs is followed by hybridization with a 3 P-labeled probe which is specific for rep-negative AAVs. Infectious rep-negative AAV particles are detected.
  • HeCMI g cells are co-transfected with the above AAV-Rep mutant pTAV 2-3 and the expression plasmid HGO.
  • the cells are incubated until the adenovirus-induced cytopathic effect (approx. 48 h) and then harvested by freeze-thaw lysis and ultrasound treatment in a hypotonic buffer. The cell fragments are centrifuged off, the AAV particles are in the supernatant. These also show up as infectious.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne la préparation de mutants d'AAV rep-négatifs et des cellules pouvant être utilisées à cet effet. L'invention concerne en outre un plasmide d'expression pouvant être utilisé pour la fabrication de ces cellules.
PCT/DE1995/001429 1994-10-13 1995-10-12 Preparation de mutants d'aav rep-negatifs et cellules pouvant etre utilisees a cet effet WO1996012010A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP95934604A EP0785991A1 (fr) 1994-10-13 1995-10-12 Preparation de mutants d'aav rep-negatifs et cellules pouvant etre utilisees a cet effet
JP8512845A JPH10507352A (ja) 1994-10-13 1995-10-12 ｒｅｐ陰性ＡＡＶ変異体の調製およびそれに使用可能な細胞

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19944436664 DE4436664A1 (de) 1994-10-13 1994-10-13 Bereitstellung von rep-negativen AAV-Mutanten und hierfür verwendbare Zellen
DEP4436665.5 1994-10-13
DE19944436665 DE4436665C2 (de) 1994-10-13 1994-10-13 Bereitstellung von rep-negativen AAV-Mutanten und hierfür verwendbare Zellen
DEP4436664.7 1994-10-13

Publications (1)

Publication Number Publication Date
WO1996012010A1 true WO1996012010A1 (fr) 1996-04-25

Family

ID=25941026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1995/001429 WO1996012010A1 (fr) 1994-10-13 1995-10-12 Preparation de mutants d'aav rep-negatifs et cellules pouvant etre utilisees a cet effet

Country Status (4)

Country Link
EP (1) EP0785991A1 (fr)
JP (1) JPH10507352A (fr)
CA (1) CA2202664A1 (fr)
WO (1) WO1996012010A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010088A1 (fr) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
WO1999027110A1 (fr) * 1997-11-21 1999-06-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. FORMES HORMONO-DEPENDANTES DU VIRUS ADENO-ASSOCIE, PROTEINES Rep, SEQUENCES D'ADN CODANT POUR CES PROTEINES, VECTEURS LES CONTENANT ET PROCEDES REGULATEURS DE LEUR ACTIVITE INTRACELLULAIRE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001070A1 (fr) * 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Conditionnement a haute efficacite de virus adeno-associe mutant utilisant la suppression d'ambre
WO1995013365A1 (fr) * 1993-11-09 1995-05-18 Targeted Genetics Corporation Production de titres eleves de vecteurs d'aav recombinants
WO1995013392A1 (fr) * 1993-11-09 1995-05-18 Medical College Of Ohio Lignees cellulaires stables aptes a exprimer le gene de replication du virus adeno-associe
WO1995014771A1 (fr) * 1993-11-24 1995-06-01 GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: National Institutes of Health Systemes vectoriels destines a la generation de particules d'un virus ayant les caracteristiques d'un adenovirus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001070A1 (fr) * 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Conditionnement a haute efficacite de virus adeno-associe mutant utilisant la suppression d'ambre
WO1995013365A1 (fr) * 1993-11-09 1995-05-18 Targeted Genetics Corporation Production de titres eleves de vecteurs d'aav recombinants
WO1995013392A1 (fr) * 1993-11-09 1995-05-18 Medical College Of Ohio Lignees cellulaires stables aptes a exprimer le gene de replication du virus adeno-associe
WO1995014771A1 (fr) * 1993-11-24 1995-06-01 GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES: National Institutes of Health Systemes vectoriels destines a la generation de particules d'un virus ayant les caracteristiques d'un adenovirus

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
B.A. ANTONI ET AL.: "Adeno-associated virus rep protein inhibits human immunodeficiency virus type 1 production in human cells", J. VIROLOGY, vol. 65, no. 1, AM.SOC.MICROBIOL.,WASHINGTON,US, pages 396 - 404 *
B.J. THOMSON ET AL.: "Human herpesvirus 6 HHV-6) is a helper for adeno-associated virus type 2 (AAV-2) and the AAV-2 rep gene homologue in HHV-6 can mediate AAV-2 DNA replication and regulate gene expression", VIROLOGY, vol. 204, no. 1, ACADEMIC PRESS, INC.,NEW YORK, US, pages 304 - 311 *
HOELSCHER C ET AL: "Cell lines inducibly expression the adeno-associated virus ( AAV ) rep gene: Requirements for productive replication of rep-negative AAV mutants.", JOURNAL OF VIROLOGY 68 (11). 1994. 7169-7177. ISSN: 0022-538X *
HOELSCHER C ET AL: "High-level expression of adeno-associated virus (AAV) Rep78 or Rep68 protein is sufficient for infectious-particle formation by a rep -negative AAV mutant.", JOURNAL OF VIROLOGY 69 (11). 1995. 6880-6885. ISSN: 0022-538X *
K.A. VINCENT ET AL.: "Replication and packaging of HIV envelope genes in a novel adeno-associated virus vector system", VACCINES 90, MODERN APPROACHES TO NEW VACCINES, vol. 90, CSH LABORATORY PRESS, NEW YORK, US, pages 353 - 359 *
KLEINSCHMIDT J A ET AL: "Sequence elements of the adeno-associated virus rep gene required for suppression of herpes-simplex-virus induced DNA amplification.", VIROLOGY 206 (1). 1995. 254-262. ISSN: 0042-6822, 10 January 1995 (1995-01-10) *
M.S.H. KO AND T. TAKANO: "A highly inducible system of gene expression by positive feedback production of glucocorticoid receptors", DNA, vol. 8, no. 2, MARY ANN LIEBERT, INC., PUBLISHERS,NEW YORK, US, pages 127 - 133 *
RITTNER K ET AL: "ADENO-ASSOCIATED VIRUS TYPE 2-MEDIATED INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 HIV-1 REPLICATION INVOLVEMENT OF P78REP/P68REP AND THE HIV-1 LONG TERMINAL REPEAT.", J GEN VIROL 73 (11). 1992. 2977-2981. CODEN: JGVIAY ISSN: 0022-1317 *
S.K. MCLAUGHLIN ET AL.: "Adeno-associated virus general transduction vector: Analysis of proviral structures", J. VIROLOGY, vol. 62, no. 6, AM.SOC.MICROBIOL.,WASHINGTON,US, pages 1963 - 1973 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010088A1 (fr) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
WO1999027110A1 (fr) * 1997-11-21 1999-06-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. FORMES HORMONO-DEPENDANTES DU VIRUS ADENO-ASSOCIE, PROTEINES Rep, SEQUENCES D'ADN CODANT POUR CES PROTEINES, VECTEURS LES CONTENANT ET PROCEDES REGULATEURS DE LEUR ACTIVITE INTRACELLULAIRE
US6753419B1 (en) 1997-11-21 2004-06-22 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. DNA molecules encoding hormone-dependent forms of the adeno-associated virus rep proteins

Also Published As

Publication number Publication date
CA2202664A1 (fr) 1996-04-25
EP0785991A1 (fr) 1997-07-30
JPH10507352A (ja) 1998-07-21

Similar Documents

Publication Publication Date Title
DE3586520T2 (de) Herpes simplex-virus als vektor.
DE69936104T2 (de) Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
DE69114997T2 (de) Von Adeno-assoziierte Viren rekombinante Vektoren.
DE69532801T2 (de) Rekombinanter Bakulovirus und seine Verwendung zur Herstellung monoklonaler Antikörper
DE60024302T2 (de) Zelllinien und konstrukte für die herstellung von e1-deletierten adenoviren in abwesenheit von replikationskompetentem adenovirus
DE60310297T2 (de) Methode für die direkte Gewinnung und Amplifikation von integrierten Viren aus zellulärer Gewebe-DNA
DE10044384A1 (de) Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
DE69030740T2 (de) Rekombinantes DNS-Verfahren und Wirtszellen
DE69101634T2 (de) Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
DE69631480T2 (de) Helfersystem zur wirkungssteigerung der aav-vektorproduktion
DE69332498T2 (de) DNS der Integrationsstelle des menschlichen Adenassoziierten Virus und seine Verwendung
EP1397499B1 (fr) Plasmides auxiliaires aav permettant l'encapsidation sans virus auxiliaire et le pseudotypage de vecteurs aav
DE4436664A1 (de) Bereitstellung von rep-negativen AAV-Mutanten und hierfür verwendbare Zellen
DE4407859C1 (de) Vektor für die leberspezifische Gentherapie
EP0785991A1 (fr) Preparation de mutants d'aav rep-negatifs et cellules pouvant etre utilisees a cet effet
EP1093524B1 (fr) Virus herpetiques recombines pour la production de virus recombines associes aux adenovirus
EP1448782A1 (fr) Production optimale de vecteurs viraux derives de parvovirus, dans des cellules d'encapsidation et de production, par infection a hsv ou traitement avec des inhibiteurs de la methylation d'adn
EP1412510B1 (fr) Plasmides d'encapsidation de vecteurs aav pour la production, sans virus assistant, de particules d'aav de type sauvage ou de particules d'aav pseudotypees par transfection unique
DE4436665C2 (de) Bereitstellung von rep-negativen AAV-Mutanten und hierfür verwendbare Zellen
EP0934423B1 (fr) Adn de virus associe aux adenovirus comportant des sequences de virus assistant
DD279503A5 (de) Verfahren zur einschleusung viraler dns in pflanzliches material
DE69636456T2 (de) In-vitro verpackung von adeno-assoziierten virus dns
DE19608751B4 (de) Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen
WO1996018737A2 (fr) Vecteurs et virus utilises pour la therapie genique
EP0954592A1 (fr) Systeme de production de vecteurs de virus aav

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2202664

Country of ref document: CA

Ref country code: CA

Ref document number: 2202664

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995934604

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995934604

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 817492

Date of ref document: 19971219

Kind code of ref document: A

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1995934604

Country of ref document: EP